Griffin Asset Management Inc. lessened its holdings in Allergan plc (NYSE:AGN) by 72.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,275 shares of the company’s stock after selling 3,385 shares during the period. Griffin Asset Management Inc.’s holdings in Allergan were worth $209,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Avestar Capital LLC purchased a new position in Allergan in the 4th quarter valued at approximately $113,000. Focused Wealth Management Inc boosted its position in Allergan by 4,444.4% in the 4th quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after buying an additional 800 shares during the period. BB&T Investment Services Inc. boosted its position in Allergan by 1,308.2% in the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after buying an additional 641 shares during the period. Acropolis Investment Management LLC purchased a new position in Allergan in the 4th quarter valued at approximately $153,000. Finally, Field & Main Bank purchased a new position in Allergan in the 4th quarter valued at approximately $155,000. 77.96% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

In related news, CEO Brent L. Saunders purchased 3,300 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The shares were purchased at an average cost of $152.53 per share, for a total transaction of $503,349.00. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Joseph H. Boccuzi purchased 900 shares of the business’s stock in a transaction that occurred on Monday, March 5th. The shares were bought at an average price of $143.42 per share, for a total transaction of $129,078.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 8,095 shares of company stock worth $1,258,081 over the last quarter. 0.36% of the stock is owned by company insiders.

Shares of Allergan stock opened at $163.70 on Thursday. Allergan plc has a one year low of $142.81 and a one year high of $256.80. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.06 and a current ratio of 1.16. The company has a market cap of $56,995.17, a price-to-earnings ratio of -12.20, a P/E/G ratio of 1.16 and a beta of 1.29.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The firm had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same period last year, the business earned $3.90 EPS. Allergan’s revenue for the quarter was up 12.0% compared to the same quarter last year. analysts predict that Allergan plc will post 15.58 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be paid a dividend of $0.72 per share. This is a positive change from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a yield of 1.76%. The ex-dividend date is Tuesday, February 27th. Allergan’s dividend payout ratio (DPR) is currently -21.46%.

AGN has been the subject of several recent research reports. Zacks Investment Research cut shares of Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. TheStreet cut shares of Allergan from a “c-” rating to a “d+” rating in a research report on Monday, December 4th. Morgan Stanley set a $200.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Wednesday, December 6th. Deutsche Bank restated a “buy” rating and issued a $215.00 price objective on shares of Allergan in a report on Tuesday, January 9th. Finally, Vetr upgraded shares of Allergan from a “sell” rating to a “hold” rating and set a $189.60 price objective on the stock in a report on Friday, January 26th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $224.02.

COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/allergan-plc-agn-shares-sold-by-griffin-asset-management-inc/1957835.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.